- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Cramer previews important earnings reports scheduled for the coming week.
Gilead Sciences (GILD) is scheduled to report 2016 third quarter earnings after Tuesday's market close.
Gilead is under enormous pressure from investors to acquire companies or develop new drugs from its pipeline.
Celgene is not some dinky micro-cap biotech lacking the resources or knowledge to conduct a rigorous clinical trial, so omitting a placebo arm from the GED-0301 study is inexcusable.